ASTRAL 2009

1 Treatments

Studied treatment  revascularization in addition to medical therapy

Control treatment  medical therapy alone

Concomittant treatments  -

Age (years)  70.5 y

stent (%)  93%

cross over from the control arm to the catheter ablation arm  3.2%

MEn (%)  63%

2 Patients

Patients  patients with atherosclerotic renovascular disease

Inclusion criteria  -

Exclusion criteria  -

indication  Resistant HTN or unexplained CRI

Diabetes (%)  30%

baseline serum cretinine (mg/dl)  2 mg/dl

History of hypertension (%)  98%

3 Methods

Blinding  open

Design  Parallel groups

Centers  -

Geographical area  United Kingdom, Australia, New Zealand

Sizes  403/403
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cause death</td>
<td>79/403</td>
<td>81/403</td>
<td>0.98</td>
<td>[0.69; 1.38]</td>
</tr>
<tr>
<td>Heart Failure</td>
<td>-/403</td>
<td>-/403</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Stroke</td>
<td>19/403</td>
<td>18/403</td>
<td>1.06</td>
<td>[0.55; 2.04]</td>
</tr>
<tr>
<td>Worsening renal failure</td>
<td>46/403</td>
<td>47/403</td>
<td>0.98</td>
<td>[0.64; 1.51]</td>
</tr>
<tr>
<td>Number of anti-hypertensive drugs at end of study</td>
<td>-/403</td>
<td>-/403</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References